Stress-induced cellular responses in immunogenic cell death: Implications for cancer immunotherapy.

Radogna, Flavia; Diederich, Marc
Biochemical pharmacology
2018Jul ; 153 ( 7 ) :12-23.
ÀúÀÚ »ó¼¼Á¤º¸
Radogna, Flavia - Laboratoire de Biologie Moleculaire et Cellulaire du Cancer, Hopital Kirchberg 9, rue Edward Steichen, L-2540 Luxembourg, Luxembourg.
Diederich, Marc - College of Pharmacy, Seoul National University, 1 Gwanak-ro, Gwanak-gu, Seoul 08826, Republic of Korea. Electronic address marcdiederich@snu.ac.kr.
ABSTRACT
Cancer is evading the host's defense mechanisms leading to avoidance of immune destruction. During tumor progression, immune-evading cancer cells arise due to selective pressure from the hypoxic and nutrient-deprived microenvironment. Thus, therapies aiming at re-establishing immune destruction of pathological cells constitute innovating anti-cancer strategies. Accumulating evidence suggests that selected conventional chemotherapeutic drugs increase the immunogenicity of stressed and dying cancer cells by triggering a form of cell death called immunogenic cell death (ICD), which is characterized by the release of danger-associated molecular patterns (DAMPs). In this review, we summarize the effects of ICD inducers on DAMP signaling leading to adjuvanticity and antigenicity. We will discuss the associated stress response pathways that cause the release of DAMPs leading to improved immune recognition and their relevance in cancer immunotherapy. Our aim is to highlight the contribution of adaptive immunity to the long-term clinical benefits of anticancer treatments and the properties of immune memory that can protect cancer patients against relapse. CI - Copyright ??2018. Published by Elsevier Inc.
keyword
Autophagy; Cancer immunotherapy; Danger-associated molecular pattern; ER stress; Immunogenic cell death; Necroptosis
¸µÅ©

ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This study highlighted the contribution of adaptive immunity to the long-term clinical benefits of anticancer treatments and the properties of immune memory that can protect cancer patients against relapse.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
https://doi.org/10.1016/j.bcp.2018.02.006
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå